SG Americas Securities’s Soleno Therapeutics SLNO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
Sell
-19,139
Closed -$641K 3640
2026
Q1
$641K Sell
19,139
-21,059
-52% -$826K ﹤0.01% 2038
2025
Q4
$1.86M Buy
40,198
+25,412
+172% +$1.39M ﹤0.01% 1574
2025
Q3
$1M Buy
+14,786
New +$1.1M ﹤0.01% 1460
2025
Q2
Sell
-4,397
Closed -$314K 3529
2025
Q1
$314K Buy
4,397
+350
+9% +$17K ﹤0.01% 2176
2024
Q4
$182K Sell
4,047
-2,039
-34% -$106K ﹤0.01% 2243
2024
Q3
$307K Sell
6,086
-7,855
-56% -$376K ﹤0.01% 2130
2024
Q2
$569K Buy
+13,941
New +$591K ﹤0.01% 1606
2021
Q3
Sell
-19,938
Closed -$341K 3893
2021
Q2
$341K Buy
+19,938
New +$337K ﹤0.01% 2111
2020
Q3
Sell
-1,200
Closed -$40K 3375
2020
Q2
$40K Buy
+1,200
New +$52K ﹤0.01% 3569

SG Americas Securities's SLNO Position: Q2 2026 in Review

SG Americas Securities sold out of Soleno Therapeutics (SLNO) in Q2 2026, closing a stake of 19,139 shares — an estimated $641K sold.

SG Americas Securities first reported a position in SLNO in Q2 2020 and held it in 9 quarters. The position peaked at $1.86M in Q4 2025. 0 funds tracked by Wall St. Rank hold SLNO as of Q2 2026.

  • SG Americas Securities reported no remaining Soleno Therapeutics position as of Q2 2026 after selling out during the quarter.
  • SG Americas Securities sold 19,139 Soleno Therapeutics shares in Q2 2026, an estimated $641K.
  • SG Americas Securities first reported a position in Soleno Therapeutics in Q2 2020 and held it in 9 quarters.
  • SG Americas Securities's Soleno Therapeutics position peaked at $1.86M in Q4 2025.
  • 0 funds tracked by Wall St. Rank held Soleno Therapeutics as of Q2 2026.

Based on SG Americas Securities's 13F filing for Q2 2026, filed 7 Aug 2026.